Observational studyRespiratory research2026
Integrated phenotyping identifies reproducible prognostic subgroups in idiopathic pleuroparenchymal fibroelastosis.
Observational study in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundIdiopathic pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease characterized by upper-lobe-predominant fibrosis and heterogeneous prognosis. An integrated phenotype classification incorporating clinical, radiological and biological markers has not been established.
methodsWe conducted a retrospective observational study of 32 patients with idiopathic PPFE in an exploratory cohort and 37 patients in a separate validation cohort. Unsupervised k-means clustering was performed using % forced vital capacity (%FVC), residual volume/total lung capacity (RV/TLC), serum KL-6 levels, and extent of fibrotic lesions on quantitative computed tomography. Leukocyte telomere length (LTL) was measured using quantitative PCR and age-adjusted. Survival was assessed using Kaplan-Meier and Cox regression models. A simplified prognostic score was constructed using predefined clinical thresholds, and its discriminative performance was evaluated using the concordance index (C-index) with bootstrap-derived confidence intervals. Sensitivity analyses using multiple imputation were performed to assess robustness.
resultsTwo distinct phenotypic clusters were identified in the exploratory cohort (Cluster 1, n = 15; Cluster 2, n = 17). Cluster 2 showed a severe fibrotic phenotype characterized by lower %FVC, higher RV/TLC, higher KL-6 levels, and greater fibrotic extent, and was associated with significantly worse survival (adjusted hazard ratio, 8.63; 95% CI, 1.06-70.4). Similar phenotypic separation and prognostic differences were reproduced in the validation cohort. The four-variable scoring system reproducibly stratified patients into three risk categories with stepwise prognostic separation in both cohorts. The model demonstrated moderate-to-good discriminative ability, with a C-index of 0.74 (95% CI, 0.59-0.88) in the exploratory cohort and 0.84 (95% CI, 0.74-0.92) in the validation cohort. In contrast, age-adjusted LTL in PPFE was not significantly shorter than in healthy controls and was not associated with survival.
conclusionsIntegrated phenotyping using quantitative CT and clinical indicators identifies reproducible prognostic subgroups in idiopathic PPFE, whereas telomere shortening does not appear to play a major prognostic role. A simple scoring system may provide clinically applicable risk stratification.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.